LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Trial Profile

LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Betamethasone-dipropionate/calcipotriol (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms PSO-ABLE
  • Sponsors LEO Pharma
  • Most Recent Events

    • 19 Jul 2017 Results of post hoc analysis (n=50) published in the British Journal of Dermatology
    • 24 Feb 2017 Results (n=159) of a subgroup analysis assessing Cal/BD foam and gel in patients with moderate-to-severe psoriasis, published in the American Journal of Clinical Dermatology.
    • 08 Mar 2016 Results assessing health-related quality of life presented at the 74th Annual Meeting of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top